title: ÐÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ðµ Ð²Ð»Ð¸ÑÐ½Ð¸Ñ Ð¸Ð½Ð´ÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð´Ð¸Ð¾ÑÐµÐ·Ð¸ÑÑÐµÐ½ÑÐ½Ð¾ÑÑÐ¸ Ð½Ð° ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ðµ Ð»ÐµÐºÐ°ÑÑÑÐ²ÐµÐ½Ð½Ð¾Ð¹ ÑÑÑÐ¾Ð¹ÑÐ¸Ð²Ð¾ÑÑÐ¸ Ð½Ð° Ð¼Ð¾Ð´ÐµÐ»Ð¸ Ð°ÑÑÐ¸ÑÐ½Ð¾Ð¹ Ð°Ð´ÐµÐ½Ð¾ÐºÐ°ÑÑÐ¸Ð½Ð¾Ð¼Ñ Ð­ÑÐ»Ð¸Ñ Ð°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: The study of the effect of induced radioresistance on the development of drug resistance on the model of ascitic adenocarcinoma of Ehrlich
Creators: name: ÐÑÐ»Ð°ÐºÐ¾Ð², ÐÐ³Ð½Ð°ÑÐ¸Ð¹
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: Ð°Ð´ÐµÐ½Ð¾ÐºÐ°ÑÑÐ¸Ð½Ð¾Ð¼Ð° Ð­ÑÐ»Ð¸Ñ Ð°
ÑÐ°Ð´Ð¸Ð¾ÑÐµÐ·Ð¸ÑÑÐµÐ½ÑÐ½Ð¾ÑÑÑ
Ð»ÑÑÐµÐ²Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
Ð¾Ð½ÐºÐ¾Ð»Ð¾Ð³Ð¸Ñ
ÑÐ¸ÑÐ¾Ð¼ÐµÑÑÐ¸Ñ
ÑÐ¸ÑÐ¿Ð»Ð°ÑÐ¸Ð½
Ð³Ð°Ð¼Ð¼Ð°-Ð¸Ð·Ð»ÑÑÐµÐ½Ð¸Ðµ
Ð´Ð¾Ð·Ð¸Ð¼ÐµÑÑÐ¸Ñ
Ehrlichs adenocarcinoma
radioresistance
radiation therapy
oncology
cytometry
cisplatin
gamma-rays
dosimetry

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¾ÑÐµÐ½ÐºÐµ ÑÑÐ²ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½Ð¾ÑÑÐ¸ ÑÑÐ±Ð¿Ð¾Ð¿ÑÐ»ÑÑÐ¸Ð¹ ÐºÐ»ÐµÑÐ¾Ðº Ð»Ð¸Ð½Ð¸Ð¸ Ð°Ð´ÐµÐ½Ð¾ÐºÐ°ÑÑÐ¸Ð½Ð¾Ð¼Ñ Ð­ÑÐ»Ð¸ÑÐ° Ñ ÑÐ°Ð´Ð¸Ð¾ÑÐµÐ·Ð¸ÑÑÐµÐ½ÑÐ½ÑÐ¼ ÑÐµÐ½Ð¾ÑÐ¸Ð¿Ð¾Ð¼ Ðº ÑÐ¸Ð¼Ð¸Ð¾ÑÐµÑÐ°Ð¿ÐµÐ²ÑÐ¸ÑÐµÑÐºÐ¾Ð¼Ñ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÑ. ÐÐ¾ ÑÐ¾Ð´Ñ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ ÑÐµÑÐ°Ð»Ð¸ÑÑ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ðµ Ð·Ð°Ð´Ð°ÑÐ¸: 1) ÐÑÐ¾Ð²ÐµÑÑÐ¸ Ð´Ð¾Ð·Ð¸Ð¼ÐµÑÑÐ¸ÑÐµÑÐºÑÑ Ð¾ÑÐµÐ½ÐºÑ Ð¾Ð±Ð¾ÑÑÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ñ Ð¸ÑÑÐ¾ÑÐ½Ð¸ÐºÐ¾Ð¼ Ð³Ð°Ð¼Ð¼Ð°-Ð¸Ð·Ð»ÑÑÐµÐ½Ð¸Ñ Ð´Ð»Ñ Ð²ÑÑÐ²Ð»ÐµÐ½Ð¸Ñ Ð¾Ð¿ÑÐ¸Ð¼Ð°Ð»ÑÐ½ÑÑ ÑÐµÐ¶Ð¸Ð¼Ð¾Ð² Ð¾Ð±Ð»ÑÑÐµÐ½Ð¸Ñ; 2) Ð¡ÑÐ¾ÑÐ¼Ð¸ÑÐ¾Ð²Ð°ÑÑ ÑÑÐ±Ð¿Ð¾Ð¿ÑÐ»ÑÑÐ¸Ð¸ ÐºÐ»ÐµÑÐ¾Ðº Ð»Ð¸Ð½Ð¸Ð¸ Ð°Ð´ÐµÐ½Ð¾ÐºÐ°ÑÑÐ¸Ð½Ð¾Ð¼Ñ Ð­ÑÐ»Ð¸ÑÐ° Ñ ÑÐ°Ð´Ð¸Ð¾ÑÐµÐ·Ð¸ÑÑÐµÐ½ÑÐ½ÑÐ¼ ÑÐµÐ½Ð¾ÑÐ¸Ð¿Ð¾Ð¼ Ð² ÑÐµÑÐ¸Ð¸ Ð¾Ð±Ð»ÑÑÐµÐ½Ð¸Ð¹ Ð¸ Ð¿ÐµÑÐµÐ²Ð¸Ð²Ð¾Ðº in vivo; 3) ÐÑÑÐ²Ð¸ÑÑ ÐºÐ¾Ð»Ð¸ÑÐµÑÑÐ²ÐµÐ½Ð½ÑÐµ Ð¸ ÐºÐ°ÑÐµÑÑÐ²ÐµÐ½Ð½ÑÐµ ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐ¸ ÑÐ°Ð´Ð¸Ð¾ÑÐµÐ·Ð¸ÑÑÐµÐ½ÑÐ½ÑÑ ÑÑÐ±Ð¿Ð¾Ð¿ÑÐ»ÑÑÐ¸Ð¹ ÐºÐ»ÐµÑÐ¾Ðº Ð»Ð¸Ð½Ð¸Ð¸ Ð°Ð´ÐµÐ½Ð¾ÐºÐ°ÑÑÐ¸Ð½Ð¾Ð¼Ñ Ð­ÑÐ»Ð¸ÑÐ°; 4) ÐÑÐµÐ½Ð¸ÑÑ ÑÑÐ²ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½Ð¾ÑÑÑ ÑÐ°Ð´Ð¸Ð¾ÑÐµÐ·Ð¸ÑÑÐµÐ½ÑÐ½ÑÑ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ ÑÑÐ±Ð¿Ð¾Ð¿ÑÐ»ÑÑÐ¸Ð¹ Ð°Ð´ÐµÐ½Ð¾ÐºÐ°ÑÑÐ¸Ð½Ð¾Ð¼Ñ Ð­ÑÐ»Ð¸ÑÐ° Ðº ÑÐ¸ÑÐ¾ÑÑÐ°ÑÐ¸ÑÐµÑÐºÐ¾Ð¼Ñ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÑ. ÐÑÐµÐ½ÐºÐ° ÑÐ°Ð´Ð¸Ð¾ÑÑÐ²ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½Ð¾ÑÑÐ¸ Ð¸ ÑÑÐ²ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½Ð¾ÑÑÐ¸ Ðº ÑÐ¸ÑÐ¿Ð»Ð°ÑÐ¸Ð½Ñ Ð¿ÑÐ¾Ð²Ð¾Ð´Ð¸Ð»Ð°ÑÑ Ð¿Ð¾ÑÑÐµÐ´ÑÑÐ²Ð¾Ð¼ Ð´ÐµÑÐµÐºÑÐ¸Ð¸ Ð°Ð¿Ð¾Ð¿ÑÐ¾Ð·Ð° Ð½Ð° Ð¿ÑÐ¾ÑÐ¾ÑÐ½Ð¾Ð¼ ÑÐ¸ÑÐ¾Ð¼ÐµÑÑÐµ. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð¿Ð¾Ð»ÑÐ»ÐµÑÐ°Ð»ÑÐ½Ð°Ñ Ð´Ð¾Ð·Ð° Ð´Ð»Ñ ÑÑÐ±Ð¿Ð¾Ð¿ÑÐ»ÑÑÐ¸Ð¸ ÐºÐ»ÐµÑÐ¾Ðº Ð»Ð¸Ð½Ð¸Ð¸ Ð°Ð´ÐµÐ½Ð¾ÐºÐ°ÑÑÐ¸Ð½Ð¾Ð¼Ñ Ð­ÑÐ»Ð¸ÑÐ°, ÑÐ¾ÑÑÐ°Ð½ÑÑÑÐµÐ¹ Ð¶Ð¸Ð·Ð½ÐµÑÐ¿Ð¾ÑÐ¾Ð±Ð½Ð¾ÑÑÑ Ð¿Ð¾ÑÐ»Ðµ Ð¾Ð±Ð»ÑÑÐµÐ½Ð¸Ñ Ð´Ð¾Ð·Ð¾Ð¹ 40 ÐÑ Ð½Ð°ÑÐ¾Ð´Ð¸ÑÑÑ Ð² Ð¸Ð½ÑÐµÑÐ²Ð°Ð»Ðµ 45â55 Ð¼ÐºÐ¼Ð¾Ð»Ñ. ÐÐ»Ñ ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÑÐ¿Ð¿Ñ Ð¿Ð¾Ð»ÑÐ»ÐµÑÐ°Ð»ÑÐ½Ð°Ñ Ð´Ð¾Ð·Ð° Ð½Ð°ÑÐ¾Ð´Ð¸ÑÑÑ Ð² Ð¸Ð½ÑÐµÑÐ²Ð°Ð»Ðµ 15â25 Ð¼ÐºÐ¼Ð¾Ð»Ñ. ÐÑÐ¸ Ð½Ð°Ð¿Ð¸ÑÐ°Ð½Ð¸Ð¸ Ð»Ð¸ÑÐµÑÐ°ÑÑÑÐ½Ð¾Ð³Ð¾ Ð¾Ð±Ð·Ð¾ÑÐ° Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð»Ð¸ÑÑ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ðµ Ð±Ð°Ð·Ñ Ð´Ð°Ð½Ð½ÑÑ: eLIBRARY.ru, PubMed. Ð¡ÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÑÑ Ð¾Ð±ÑÐ°Ð±Ð¾ÑÐºÑ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ°Ð»ÑÐ½ÑÑ Ð´Ð°Ð½Ð½ÑÑ Ð¾ÑÑÑÐµÑÑÐ²Ð»ÑÐ»Ð¸ Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ Ð¿Ð°ÐºÐµÑÐ¾Ð² Ð¿ÑÐ¾Ð³ÑÐ°Ð¼Ð¼ Microsoft Office, Cytobank.
description: This work is devoted to assessing the sensitivity of subpopulations of Ehrlich adenocarcinoma cells with a radioresistant phenotype to a chemotherapeutic drug. In the course of the study, the following tasks were solved: 1) Conduct a dosimetric assessment of equipment with a gamma radiation source to identify optimal irradiation modes; 2) To form subpopulations of Ehrlich adenocarcinoma cells with a radioresistant phenotype in a series of irradiations and in vivo inoculations; 3) To identify quantitative and qualitative characteristics of radioresistant subpopulations of Ehrlich adenocarcinoma cells; 4) To evaluate the sensitivity of radioresistant tumor subpopulations of Ehrlichs adenocarcinoma to a cytostatic drug. Radiosensitivity and sensitivity to cisplatin were evaluated by detecting apoptosis on a flow cytometer. As a result, the half-year dose for a subpopulation of cells of the Ehrlich adenocarcinoma line that remains viable after irradiation with a dose of 40 Gy is in the range of 45â55 Âµmol. For the control group, the median lethal dose is in the range of 15â25 Âµmol. When writing the literary review, the following databases were used: eLIBRARY, PubMed. Statistical processing of experimental data was carried out using the Microsoft Office software package, Cytobank.